- Candel reports prostate cancer drug's long-term data ahead of FDA filingCandel Therapeutics produced long-term follow-up data that may bolster the case for its prostate cancer drug that's heading to the FDA for marketing approval later this year. The company followed…Endpoints · 2mo ago↗ source
- Post-Hoc Live: Makary's out at FDA and what comes nextMarty Makary resigned as FDA commissioner on Tuesday after a turbulent tenure at the head of the agency. Makary was scheduled to sit down with senior reporter Max Bayer this week at ...Endpoints · 2mo ago↗ source
- Aardvark's next move after clinical hold; Alumis' verdict on Acelyrin assetPlus, news about Tenaya’s TN-401 and Taiho’s Inqovi. 📉 Aardvark to unblind rare disease trial following clinical hold: The FDA has placed a full clinical hold on the company's candidate for ...